Michael Ciraolo

ImClone LLC develops targeted biologic treatments designed for the medical needs of patients with tumors. The company was founded in 1984 and is headquartered in Bridgewater, NJ.

Asuragen, Inc. develops molecular diagnostic products. Its products include AmplideX and QuantideX. It uses genomics to drive patient management through clinical testing solutions. The company was founded in March 2006 by Matthew M. Winkler and is headquartered in Austin, TX.

The Scripps Research Institute is a private, non-profit research organizations that performs basic biomedical research in molecular & cellular biology, chemistry, immunology and neuroscience. They receive the majority of its funding from federal agencies such as the National Institutes of Health. The organization also partners with pharmaceutical companies and is affiliated with the Scripps hospital group. The organization was founded in 1955 and is headquartered in La Jolla, California.

Advanced Health Media LLC provides consulting tools and services for pharmaceutical companies. It offers e-contracting, e-slide library, data management, event logistics, contract and financial management, reporting and compliance support and issue resolution. The company was founded by Kevin McMurtry and Joseph Luzi in 1999 and is headquartered in New Providence, NJ.

Accelerator Services Corp (Accelerator Services) is a venture capital firm founded in 2003 by Carl Weissman and Rodney F. Burgar. The firm is headquartered in Seattle, Washington.

BioCentury Publications, Inc. publishes a bioindustry news. It provides information, analysis and data for biotechnology and pharmaceutical companies, investors, academia, and government on the strategic issues essential to the formation, development and sustainability of life science ventures worldwide. The company was founded by David Flores and Karen Bernstein in 1992 and is headquartered in Redwood City, CA.

Vector Technologies LLC engages in the provision of technical surveillance countermeasure solutions. Its product portfolio includes Guardian G2, Guardian, Sentinel, Defender, Warrior, portable shielded enclosure, and secure mobile telecommunications system (STMS). The firm also offers surveys and sweeps, inspections, advice and assistance, and custom design and engineering services. The company was founded in February 2003 and is headquartered in Arlington, VA.

AptamiR Therapeutics, Inc. develops a revolutionary treatment for human obesity. The private company is based in Naples, FL. The company was founded by Marc Thibonnier.

Xenikos BV focuses on the development of immunotherapies for the treatment of patients suffering from immune diseases. It is developing a combination of two toxin-loaded anti-T-cell antibodies, T-Guard, as a therapeutic tool for resetting the body's immune system in T-cell mediated diseases. The company was founded by Ypek van Oosterhout in September 2009 and is headquartered in Nijmegen, the Netherlands.

The Foundation for Angelman Syndrome Therapeutics (FAST) is a non-governmental funding organization that supports research for Angelman syndrome. The non-profit company is based in Austin, TX. The organization is focused on finding prospective treatments for the syndrome. FAST Athletes is a program led by high-class athletes in the Angelman syndrome community who help support the mission of FAST. The company was founded in 2008 by Paula M. Evans.

ZSX Medical LLC engages in the development of medical devices for surgeons. It specializes solutions for improving minimally-invasive surgery. The company was founded by Daniel Mazzucco and Eric Rugart in 2009 and is headquartered in Philadelphia, PA.

Broad Street Angels (BSA) is a venture capital firm founded in 2016 by Robert J. Ciaruffoli, Katherine O’Neill, RoseAnn Rosenthal and Doc Parghi. The firm is headquartered in Philadelphia, Pennsylvania.

Cygnal Therapeutics, Inc. develops drugs for cancer, immunological diseases and regenerative processes. The company was founded by Noubar Afeyan, Avak Kahvejian and Jordi Mata-Fink in 2017 and is headquartered in Cambridge, MA.

Stablix, Inc. is a biotechnology company based in New York, NY. The company is focused on establishing a new paradigm for tackling diverse diseases by harnessing the power of the body's own cellular machinery through targeted protein stabilization. Stablix's restored™ platform generates heterobifunctional small molecules (restoracs™) that selectively recruit active deubiquitinases (dubs) to target proteins for precise removal of ubiquitin to restore protein function. The company is currently advancing its lead programs towards clinical studies. The company's platform is based on the work of Henry Colecraft, Ph.D., professor of physiology and cellular biophysics, and professor of pharmacology, Columbia University Irving Medical Center. Stablix was founded in June 2021 with a $63 million series A led by founding investor Versant Ventures with New Enterprise Associates (NEA), Cormorant Asset Management, Euclidean Capital, and Alexandria Venture Investments. Stuart Anthony Kingsley has been the CEO of the company since 2022.

Cytoimmune Therapeutics, Inc. is a clinical-stage biotechnology company founded in 2017 and based in Toa, Japan. The American company is focused on developing a pipeline of NK cell therapies for various types of cancer, including lung cancer, acute myeloid leukemia, solid tumors, and multiple myeloma. The private company's lead product, Cyto-102, is a track-NK cell therapy that aims to enter clinical trials in combination with atezolizumab for non-small cell lung cancer in 2022. Cytoimmune Therapeutics also offers cell therapy development and clinical manufacturing services to biotechnology companies and academia. The company's state-of-the-art clinical cell manufacturing facility is custom-built to support the development and commercialization of cutting-edge T cell or NK cell therapies. The company was founded in 2017 by Michael A. Caligiuri, William Michael Rosellini, and Jianhua Yu, Ph.D. José Eduardo Vidal has been the CEO of the company since 2021.